Press Releases

CRANBURY, N.J., Feb. 13, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its second quarter, fiscal year 2014 operating results on Tuesday, February 18, 2014 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on February […]

CRANBURY, N.J., Jan. 30, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that data from a 12-week placebo-controlled dose-ranging study using self-administered subcutaneous bremelanotide for the treatment of female sexual dysfunctions will be presented at the 16th Congress of the European Society for Sexual Medicine in Istanbul, Turkey on Friday, January 31, 2014

CRANBURY, N.J., Jan. 23, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced today that it has received approximately $1.85 million of non-dilutive funding via the State of New Jersey’s Technology Business Tax Certificate Transfer

CRANBURY, N.J., Jan. 13, 2014 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) (the “Company”) announced today that in view of the unusual market activity in common stock of the Company on Monday, January 13, 2014, the NYSE MKT (the “Exchange”) has contacted the Company in accordance with the Exchange’s usual practice. The Company stated that

CRANBURY, N.J., Dec. 2, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) announced today that Dr. Carl Spana, the Company’s chief executive officer, will participate in a “Fireside Chat” at the 25th Annual Piper Jaffray Healthcare Conference at 4:00 p.m. ET on December 4, 2013. The conference will be held at the New York Palace

CRANBURY, N.J., Nov. 14, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, today announced results for its first quarter ended September 30, 2013.  Recent Highlights Bremelanotide development for Female Sexual Dysfunction (FSD): Successful completion

CRANBURY, N.J., Nov. 13, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that it has entered into an option agreement for an exclusive license to bremelanotide for female sexual dysfunction indications in selected

CRANBURY, N.J., Nov. 12, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN), a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential, announced that the United States Patent and Trademark Office today issued two new patents to Palatin.  Both patents support Palatin’s program developing

CRANBURY, N.J., Nov. 11, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) will announce its first quarter, fiscal year 2014 operating results on Thursday, November 14, 2013 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on November 14,

CRANBURY, N.J., Oct. 28, 2013 /PRNewswire/ — Palatin Technologies, Inc. (NYSE MKT: PTN) today announced the successful completion of a clinical trial designed to demonstrate equivalence of subcutaneously administered bremelanotide via autoinjector compared to pre-filled syringe administration. Bioequivalence was achieved in this clinical trial. Palatin used pre-filled syringes in its Phase 2 clinical trials, but will